Summary of use during lactation
Alglucerase is the placenta-derived form of the enzyme, beta-glucocerebrosidase that is a normal component of human milk. Studies with alglucerase and synthetic forms of the enzyme have found very low levels of the enzyme in breastmilk. Absorption is unlikely because it is probably destroyed in the infant’s gastrointestinal tract.[1,2]. International panels of clinicians that treat Gaucher’s disease recommend breastfeeding with enzyme replacement theapy such as alglucerase.[2,3] Consider limiting the duration of breastfeeding to about 6 months to avoid excessive bone loss in the nursing mother.[2–4]
Drug levels in milk and infant serum
Maternal Levels. One woman received 60 units/kg of alglucerase intravenously. Alglucerase appeared in breastmilk in levels above the baseline control values at 2, 6, 12, 24 and 48 hours postinfusion. Concentrations ranged between 69 and 187 ng/L above baseline.[5] Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
One woman received alglucerase 30 international units/kg intravenously every 2 weeks during pregnancy and lactation. Her breastfed infant reportedly grew and developed normally.[6]
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
Imiglucerase, Taliglucerase Alfa
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.